[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated October 26, 2010. Please note that this site represents the latest program changes
and differs from the print version in some details.

633.O3.8 Myelodysplastic Syndromes: Iron Overload, Immune Mechanisms and Risk Categorization

Oral and Poster Abstracts
Oral Session
Monday, December 8, 2008: 3:30 PM-5:30 PM
303-305-307 - South (Moscone Center)
Elihu Estey, MD and Jaroslav Cermak
3:30 PM
Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial

Norbert Gattermann1, Mathias Schmid2*, Matteo Della Porta3*, Kerry Taylor4*, John F Seymour5*, Dany Habr6*, Gabor Domokos7*, Abdel Hmissi7*, Agnès Guerci-Bresler8* and Christian Rose9*

1Heinrich-Heine-University, Duesseldorf, Germany
2Hematology, University Hospital, Ulm, Germany
3Division of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Pavia, Italy
4Mater Hospital, Brisbane, Australia
5Peter MacCallum Cancer Centre, Melbourne, Australia
6Novartis, East Hanover, NJ
7Novartis, Basel, Switzerland
8CHU Brabois (Groupe Francophone des Myélodysplasies), Vandoeuvre Cédex, France
9Hôpital Saint-Vincent de Paul (Groupe Francophone des Myélodysplasies), Lille, France

3:45 PM
Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Alan F List, MD1, Maria R Baer2*, David Steensma3*, Azra Raza4*, Jason Esposito5*, Jodi Virkus6*, Carole Paley5, John Feigert7* and Emmanuel C Besa8*

1Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
2University of Maryland Medical Center, Baltimore, MD
3Mayo Clinic, Rochester, MN
4St. Vincent's Comprehensive Cancer Center, New York, NY
5Novartis Pharmaceuticals, East Hanover, NJ
6Novartis, East Hanover, NJ
7Arlington Fairfax Hematology/Oncology, Arlington, VA
8Thomas Jefferson University, Philadelphia, PA

4:00 PM
Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)

Hagop M Kantarjian1, Susan O'Brien2*, Farhad Ravandi2*, Jorge Cortes2*, Jianqin Shan2*, John M. Bennett, MD3, Alan F List, MD4, Pierre Fenaux, MD, PhD5* and Guillermo Garcia-Manero2*

1The University of Texas M. D. Anderson Cancer Center, Houston, TX
2M.D. Anderson Cancer Center, Houston, TX
3University of Rochester, Rochester, NY
4Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5Hospital Avicenne, Bobigny, France

4:15 PM
Clinical and Economic Consequences of Myelodysplastic Syndromes in the United States: An Analysis of the Medicare Database

Stuart L Goldberg, MD1, Nikita Mody-Patel, PharmD2* and E. R Chen, MPP3*

1John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
2Novartis Pharmaceuticals, East Hanover, NJ
3Quorum Consulting, San Francisco, CA

4:30 PM
Increased Number of IL-17 Producing CD4+ T Cells in Low Risk Myelodysplastic Syndrome (MDS)

Shahram Y Kordasti, MD1*, Behdad Afzali2*, Ziyi Lim1*, Wendy Ingram1*, Janet Hayden1*, Linda Barber1*, Giovanna Lombardi2*, Farzin Farzaneh, Professor1* and Ghulam J Mufti, MBBS, DM, FRCP, FRCPath3

1Haematological Medicine, King's College London, London, United Kingdom
2Nephrology and Transplantation, Immunoregulation laboratory, King's College London, London, United Kingdom
3Department of Haematological Medicine, King's College London, London, United Kingdom

4:45 PM
Investigations of Genetic Risk Factors in MDS and AML Using High-Density 6.0 Affymetrix Arrays

Bartlomiej P Przychodzen1*, Anna Malgorzata Jankowska1*, Sandra P Smieszek1*, Sanjay Ram Mohan, MD1*, Ramon V. Tiu, MD, BS1, Monika Jasek2*, Lukasz P Gondek, MD3* and Jaroslaw P Maciejewski1

1Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
21Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Experimental Hematology and Hematopoiesis Section/Internal Medicine, Cleveland Clinic, Cleveland, OH

5:00 PM
SNP-Array Based Karyotyping Complements Routine Cytogenetics in Diagnosis and Risk Stratification Schemes of MDS

Ramon V. Tiu, MD, BS1, Lukasz P Gondek, MD2*, Jungwon Huh, MD3*, Christine O'Keefe, PhD3*, Mikkael A. Sekeres, MD, MS4, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath5, Michael A McDevitt, MD, PhD6 and Jaroslaw Maciejewski, MD, PhD1

1Hematologic Oncology and Blood Disorders/Experimental Hematology and Hematopoiesis Section, Cleveland Clinic (Taussig Cancer Institute), Cleveland, OH
2Experimental Hematology and Hematopoiesis Section/Internal Medicine, Cleveland Clinic, Cleveland, OH
3Experimental Hematology and Hematopoiesis, Cleveland Clinic (Taussig Cancer Institute), Cleveland, OH
4Hematologic Oncology and Blood Disorders R35, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
5Department of Haematological Medicine, King's College London, London, United Kingdom
6Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

5:15 PM
Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome

Guillermo Sanz1, Benet Nomdedeu, MD2*, Esperanza Such3*, Teresa Bernal, MD4*, Mohamed Belkaid2*, Mª Teresa Ardanaz, MD5*, Victor Marco, MD6*, Carme Pedro, MD7*, Fernando Ramos, MD, PhD, MPH8*, Maria Consuelo del Cañizo, MD, PhD9*, Elisa Luño, MD4*, Francesc Cobo, MD4*, Felix Carbonell, MD10*, Valle Gomez, MD11*, Juan A Muñoz12*, Mari Luz Amigo, MD13*, Alicia Bailen, MD14*, Santiago Bonanad, MD15*, Mar Tormo, MD16, Rafael Andreu17*, Beatriz Arrizabalaga, MD18*, Maria J. Arilla19*, Javier Bueno, MD20*, Maria J. Requena, MD21*, Joan Bargay, MD22*, Joaquin Sanchez, MD23*, Leonor Senent, MD3*, Leonor Arenillas, MD24*, Raquel de Paz, MD, PhD25*, Blanca Xicoy, MD26*, Rafael Duarte, MD, PhD27* and Jose Cervera, MD3*

1Hematology, Hospital Universitario La Fe, Valencia, Spain
2Hematology Department, Hospital Clinic, Barcelona, Spain
3Dept. of Hematology, Hospital Universitario La Fe, Valencia, Spain
4Department of Hematology, Hospital Central de Asturias, Oviedo, Spain
5Hematology, Hospital Txagorritxu, Vitoria, Spain
6Hematology, Hospital Arnau de Vilanova, Lleida, Spain
7Clinical Hematology, IMIM, Hospital del Mar, Barcelona, Spain
8Hematology, Hospital de León, León, Spain
9Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
10Hematology, Hospital General Valencia, Valencia, Spain
11Hospital de la Princesa, Madrid, Spain
12Hematology, Hospital Puerta del Mar, Cadiz, Spain
13Hospital Morales Meseguer, Murcia, Spain
14Hospital Carlos Haya, Malaga, Spain
15Hospital de Alzira, Alzira, Spain
16Service Hematology - Oncology, Hospital Clinico University, Valencia, Spain
17MD, Hospital Doctor Peset, Valencia, Spain
18Hematology, Hospital de Cruces, Baracaldo, Spain
19Hematology, Hospital de Sagunto, Sagunto, Spain
20Hematology, Hospital Vall d'Hebron, Barcelona, Spain
21Hematology, Hospital Severo Ochoa, Leganes, Spain
22Hematology, Hospital Son Llatzer, Palma de Mallorca, Spain
23Hematology, Hospital Reina Sofia, Cordoba, Spain
24Hospital del Mar, Barcelona, Spain
25Hematology, Hospital Universitario La Paz, Madrid, Spain
26Hematology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
27Hematology, Hospital Duran i Reynals (ICO), Bellvitge, Spain

*signifies non-member of ASH